Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Medeot

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Expert Review of Hematology|November 19, 2016
How could patient reported outcomes improve patient management in chronic myeloid leukemia?Federico De Marchi, Marta Medeot, Renato Fanin, et al.
Current Stem Cell Research & Therapy|May 16, 2009
Clinical presentation, outcome and risk factors of late-onset non-infectious pulmonary complications after allogeneic stem cell transplantationFrancesca Patriarca, Venerino Poletti, Ulrich Costabel, et al.
European Journal of Haematology|May 31, 2008
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up resultsMarta Medeot, Francesco Zaja, Nicola Vianelli, et al.
European Journal of Haematology|June 16, 2010
Low-dose rituximab in adult patients with primary immune thrombocytopeniaFrancesco Zaja, Nicola Vianelli, Stefano Volpetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningChristopher G Kanakry, Paul V O'Donnell, Terry Furlong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2016
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell TransplantationFrancesca Patriarca, Chiara Cigana, Dozzo Massimo, et al.
Cancer Research|February 29, 2020
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer ImmunotherapySiri Tähtinen, Sara Feola, Cristian Capasso, et al.
European Journal of Haematology|March 26, 2014
Experts' considerations on HLA-haploidentical stem cell transplantationFrancesca Patriarca, Leo Luznik, Marta Medeot, et al.
Oncotarget|March 28, 2018
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patientsMario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Review of Hematology|November 19, 2016
How could patient reported outcomes improve patient management in chronic myeloid leukemia?Federico De Marchi, Marta Medeot, Renato Fanin, et al.
Current Stem Cell Research & Therapy|May 16, 2009
Clinical presentation, outcome and risk factors of late-onset non-infectious pulmonary complications after allogeneic stem cell transplantationFrancesca Patriarca, Venerino Poletti, Ulrich Costabel, et al.
European Journal of Haematology|May 31, 2008
Rituximab therapy in adult patients with relapsed or refractory immune thrombocytopenic purpura: long-term follow-up resultsMarta Medeot, Francesco Zaja, Nicola Vianelli, et al.
European Journal of Haematology|June 16, 2010
Low-dose rituximab in adult patients with primary immune thrombocytopeniaFrancesco Zaja, Nicola Vianelli, Stefano Volpetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 2014
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioningChristopher G Kanakry, Paul V O'Donnell, Terry Furlong, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 10, 2016
Risk Factors and Outcomes of Infections by Multidrug-Resistant Gram-Negative Bacteria in Patients Undergoing Hematopoietic Stem Cell TransplantationFrancesca Patriarca, Chiara Cigana, Dozzo Massimo, et al.
Cancer Research|February 29, 2020
Exploiting Preexisting Immunity to Enhance Oncolytic Cancer ImmunotherapySiri Tähtinen, Sara Feola, Cristian Capasso, et al.
European Journal of Haematology|March 26, 2014
Experts' considerations on HLA-haploidentical stem cell transplantationFrancesca Patriarca, Leo Luznik, Marta Medeot, et al.
Oncotarget|March 28, 2018
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patientsMario Tiribelli, Massimiliano Bonifacio, Gianni Binotto, et al.
Blood|January 5, 2017
Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamideChristopher G Kanakry, Javier Bolaños-Meade, Yvette L Kasamon, et al.
Pageof 2